Not logged in Share Save
Phase I study of bevacizumab and temsirolimus combination therapy in advanced malignancies: safety, efficacy, and ovarian cancer expansion Piha-Paul, Sarina A.; Tseng, Chieh; Thompson, Emily; Stafford, R. Jason; Le, Hung; Kang, Lei; Fu, Siqing; Tsimberidou, Apostolia; Blumenschein, George; Ahnert, Jordi Rodon; Slopis, John M.; Hong, David; Naing, Aung; Meric-Bernstam, Funda; Ng, Chaan S.; Westin, Shannon; Sood, Anil K. Share Save
Share Save
Share Save
Share Save
Share Save
Share Save
A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies Juric, Dejan; Anderson, Daniel; Dowlati, Afshin; Rodon, Jordi; Lugowska, Iwona; Mandziuk, Slawomir; Song, Yuqin; Woei-A-Jin, Feng Jung Sherida H.; Andre, Marc; Tybor, Joanna Gora; Hernandez-Rivas, Jose-Angel; Kurzrock, Razelle; Lopez-Guillermo, Armando; Schroder, David; Stec, Rafal; Berger, Allison; Chao, Bo; Chudnovsky, Aleksander; Gibbs, John P.; Long, Tao; Stroopinsky, Dina; Dong, Qi; Olszanski, Anthony J. Share Save
Pemigatinib for previously treated metastatic or unresectable central nervous system tumors with fibroblast growth factor receptor mutations or rearrangements: FIGHT-207 results Spanggaard, Iben; Matrana, Marc; Rocha Lima, Caio; Mahipal, Amit; Vieito, Maria; Hervieu, Alice; Goyal, Lipika; Rodon, Jordi; Veronese, Maria Luisa; Oliveira, Natalia; Li, Xin; Schaffer, Michael; Kesari, Santosh Share Save
A PHASE 1/2 TRIAL OF FOG-001, A FIRST-IN-CLASS DIRECT β-CATENIN:TCF4 INHIBITOR: SAFETY AND PRELIMINARY ANTITUMOR ACTIVITY IN ADAMANTINOMATOUS CRANIOPHARYNGIOMA (ACP) PATIENTS Papadopoulos, Kyriakos P.; Brastianos, Priscilla K.; Cecchini, Michael; Khushman, Moh'd; Kummar, Shivaani; Pelster, Meredith; Rodon, Jordi; Sharma, Sunil; Yaeger, Rona; Rojo, Jonathan; Wells, Amber L.; Tipps, Megan; Berry, Wade; Garofalo, Amanda; Akella, Lalith; Yu, Ziyang; Ramos, Jorge D.; Nguyen, Marie Huong; Orford, Keith; Klempner, Samuel J. Share Save
Share Save
Afatinib in patients with solid tumors with neuregulin 1 (NRG1) fusions: a case series from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study Rodon, J.; Rothe, M.; Mangat, P. K.; Garrett-Mayer, E.; Cannon, T. L.; Hobbs, E.; Kalemkerian, G. P.; Hinshaw, D. C.; Gregory, A.; Grantham, G. N.; Halabi, S.; Schilsky, R. L. Share Save
Share Save
Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials Zhao, Shen; Cheng, Ying; Wang, Qiming; Li, Xingya; Liao, Jun; Rodon, Jordi; Meng, Xiangjiao; Luo, Yongzhong; Chen, Zhendong; Wang, Wei; Yi, Tienan; Li, Yongsheng; Yin, Yongmei; Xu, Huiting; Yu, Guohua; Mi, Yanjun; Fan, Yun; Wainberg, Zev A.; Wang, Xiang; Su, Cuiyun; Yu, Qitao; Lai, Shuzhen; Sun, Longhua; Zhuang, Wu; Wang, Xian; Yang, Jiacheng; Li, Yaling; Ge, Junyou; Li, Jin; Zhang, Li Share Save
A phase I/II trial of avelumab combinations with ivuxolimab, utomilumab, and radiation therapy in patients with advanced gastrointestinal malignancies Ahmed, Jibran; Knisely, Anne; Torrado, Carlos; Stephen, Bettzy; Yang, Yali; Song, Juhee; Alshawa, Anas; Zarifa, Abdulrazzak; Jhingran, Anuja; Koay, Eugene J.; Morris, Van Karlyle; Javle, Milind; Wolff, Robert A.; Meric-Bernstam, Funda; Pant, Shubham; Rodon, Jordi; Naing, Aung Share Save
Olaparib in treatment-refractory isocitrate dehydrogenase 1 (IDH1)- and IDH2-mutant cholangiocarcinoma: Safety and antitumor activity from the phase 2 National Cancer Institute 10129 trial Cecchini, Michael; Pilat, Mary Jo; Uboha, Nataliya; Azad, Nilofer S.; Cho, May; Davis, Elizabeth J.; Ahnert, Jordi Rodon; Tinoco, Gabriel; Shapiro, Geoffrey I.; Khagi, Simon; Powers, Benjamin; Spencer, Kristen; Groisberg, Roman; Drappatz, Jan; Chen, Li; Das, Biswajit; Bao, Xun; Li, Jing; Narayan, Azeet; Vu, Dennis; Patel, Abhijit; Niger, Monica; Doroshow, Deborah; Durecki, Diane; Boerner, Scott A.; Bindra, Ranjit; Ivy, Percy; Shyr, Derek; Shyr, Yu; Lorusso, Patricia M. Share Save
Phase I trial of the combination of the pan-ErbB inhibitor neratinib and mTOR inhibitor everolimus in advanced cancer patients with ErbB family gene alterations Piha-Paul, S. A.; Tseng, C.; Tran, H. T.; Naing, A.; Dumbrava, E. E.; Karp, D. D.; Rodon, J.; Yap, T. A.; Raghav, K. P.; Damodaran, S.; Le, X.; Soliman, P. T.; Lim, J.; Meric-Bernstam, F. Share Save
First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase I dose exploration5 Rodon, J.; Prenen, H.; Sacher, A.; Villalona-Calero, M.; Penel, N.; El Helali, A.; Rottey, S.; Yamamoto, N.; Ghiringhelli, F.; Goebeler, M. E.; Doi, T.; Postel-Vinay, S.; Lin, C. -c.; Liu, C.; Chuang, C. -h.; Keyvanjah, K.; Eggert, T.; Neil, B. h. o ' Share Save
The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development Westphalen, C. B.; Martins-Branco, D.; Beal, J. R.; Cardone, C.; Coleman, N.; Schram, A. M.; Halabi, S.; Michiels, S.; Yap, C.; Andre, F.; Bibeau, F.; Curigliano, G.; Garralda, E.; Kummar, S.; Kurzrock, R.; Limaye, S.; Loges, S.; Marabelle, A.; Marchio, C.; Mateo, J.; Rodon, J.; Spanic, T.; Pentheroudakis, G.; Subbiah, V. Share Save
First results of a Phase 1 study evaluating safety, PK, PD and clinical activity of STC-15, aMETTL3 inhibitor, in patients with advanced malignancies Rodon, J.; Moser, J. C.; Papadopoulos, K. P.; Ofir-Rosenfeld, Y.; Weisser, H.; Snyder, M.; Schmalbach, T.; Barker, T.; Deshpande, D.; Skead, B.; Hester, D.; Sheth, N.; Leon, P. Saldana; Blanco-Cepeda, E.; Rausch, O.; Holz, J. B. Share Save
.png){kind=icon}
.png){kind=icon}
Not logged in.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
